Effect of intravenous N -acetylcysteine on outcomes after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial

• Published in: The Journal of thoracic and cardiovascular surgery Vol. 133; no. 1; pp. 7 - 12
• Main Authors: El-Hamamsy, Ismail, MD, Stevens, Louis-Mathieu, MD, Carrier, Michel, MD, Pellerin, Michel, MD, Bouchard, Denis, MD, Demers, Philippe, MD, Cartier, Raymond, MD, Page, Pierre, MD, Perrault, Louis P., MD, PhD
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Mosby, Inc 2007; AATS/WTSA; Elsevier
• Subjects: Acetylcysteine - administration & dosage; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents - administration & dosage; Antioxidants - administration & dosage; Biological and medical sciences; Cardiology. Vascular system; Cardiopulmonary Bypass; Cardiothoracic Surgery; Coronary Artery Bypass; Coronary heart disease; Double-Blind Method; Female; Heart; Humans; Injections, Intravenous; Interleukin-6 - blood; Male; Medical sciences; Middle Aged; Myocardial Reperfusion Injury - prevention & control; Postoperative Complications; Preoperative Care; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the heart; 25; NS; CK-MB; IL-6; N-acetylcysteine; interleukin 6; NAC; CPB; ROS; reactive oxygen species; cardiopulmonary bypass; not significant; creatine kinase; ICU; intensive care unit; CABG; 31; coronary artery bypass grafting; Heart; Thiol; Prognosis; Intravenous administration; Acetylcysteine; Cardiovascular disease; Thorax; Antioxidant; Coronary heart disease; Mucolytic; Randomization; Coronary artery bypass; Double blind study; Evolution

Objective N -acetylcysteine, a potent anti-inflammatory and antioxidant agent, is known to decrease the production of reactive oxygen species after cardiac surgery. The objective of this study was to evaluate the effects of intravenous N -acetylcysteine on clinical and biochemical outcomes after cor...